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Abstract. 
 
In previous studies we have shown that, after 
stimulation by a receptor ligand such as thrombin, tis-
sue-type plasminogen activator (tPA) and von Wille-
brand factor (vWf) will be acutely released from human 
umbilical vein endothelial cells (HUVEC). However, the 
mechanisms involved in the secretion of these two pro-
teins differ in some respects, suggesting that the two pro-
teins may be stored in different secretory granules.
By density gradient centrifugation of rat lung homo-
genates, a particle was identified that contained nearly 
all tPA activity and antigen. This particle had an aver-
age density of 1.11–1.12 g/ml, both in Nycodenz density 
gradients and in sucrose density gradients. A similar 
density distribution of tPA was found for a rat endothe-
lial cell line and for HUVEC. After thrombin stimula-
tion of HUVEC to induce tPA secretion, the amount of 
tPA present in high-density fractions decreased, con-
comitant with the release of tPA into the culture me-
dium and a shift in the density distribution of P-selectin.
vWf, known to be stored in Weibel-Palade bodies, 
showed an identical distribution to tPA in Nycodenz 
gradients. In contrast, the distribution in sucrose gradi-
ents of vWf from both rat and human lung was very dif-
ferent from that of tPA, suggesting that tPA and vWf 
were not present in the same particle.
Using double-immunofluorescence staining of HU-
VEC, tPA- and vWf-containing particles showed a dif-
ferent distribution by confocal microscopy. The distri-
bution of tPA also differed from the distribution of 
tissue factor pathway inhibitor, endothelin-1, and cave-
olin. By immunoelectronmicroscopy, immunoreactive 
tPA could be demonstrated in small vesicles morpholog-
ically different from the larger Weibel-Palade bodies. It 
is concluded that tPA in endothelial cells is stored in a 
not-previously-described, small and dense (
 
d
 
 
 
5
 
 1.11–
1.12 g/ml) vesicle, which is different from a Weibel-Palade 
body.
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1. 
 
Abbreviations used in this paper
 
: HUVEC, human umbilical vein endo-
thelial cells; TFPI, tissue factor pathway inhibitor; tPA, tissue-type plasmi-
nogen activator; vWf, von Willebrand factor.
 
O
 
f 
 
the physiologically occurring plasminogen activa-
tors, tissue-type plasminogen activator (tPA)
 
1
 
 is
the most important one in triggering physiological
fibrinolysis and thrombolysis. Transgenic mice in which
the tPA gene has been functionally disrupted (Carmeliet
and Collen, 1996
 
a
 
,
 
b
 
) and that consequently do not have
tPA circulating in their blood, show a reduced throm-
bolytic potential and an increased thrombogenic tendency.
Also, clots from which tPA has been removed (function-
ally by inactivation, or immunologically by immunoab-
sorbtion) will not lyse (Wun and Capuano, 1985, 1987).
Circulating tPA is derived from vascular endothelial cells,
which have been shown to synthesize tPA both in vivo
(Levin and del Zoppo, 1994; Lupu et al., 1995
 
b
 
; Padró et
al., 1995; Schneiderman et al., 1995) and in vitro (for re-
view see van Hinsbergh et al., 1991; Emeis et al., 1996;
Kooistra and Emeis, 1997). In vivo, tPA can also be dem-
onstrated in vascular endothelial cells by functional and
immunocytochemical techniques, although the precise lo-
calization of tPA in endothelial cells is still not settled (for
review see Emeis et al., 1996). In culture, endothelial cells
constitutively secrete tPA into the medium. Regulated se-
cretion from endothelial cells has been demonstrated as
well, both in vivo (for review see Emeis, 1988, 1996; Emeis
et al., 1996) and recently in vitro (van den Eijnden-Schrau-
wen et al., 1995, 1997).
A similar situation pertains to von Willebrand factor
(vWf), another endothelial cell protein that is synthesized
by, and stored in, the endothelium and is secreted from en-
dothelial cells by both constitutive and regulated secretion
(for review see Reinders et al., 1988; Wagner, 1990, 1993;
Mayadas and Wagner, 1991; Hop and Pannekoek, 1996).
In most experimental and clinical situations, tPA and vWf
are secreted simultaneously upon stimulation (Tranquille
and Emeis, 1990; van den Eijnden-Schrauwen et al., 1995;
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for review see Emeis, 1996). Recent data, however, sug-
gest that the regulated secretion of tPA and vWf are dif-
ferently regulated, so that the release of the two proteins
can be induced separately (van den Eijnden-Schrauwen et
al., 1997). For this to be possible, tPA should be stored in a
secretory granule different from the Weibel-Palade body
in which vWf is stored in endothelial cells (for review see
Reinders et al., 1988; Wagner, 1990, 1993). No storage
granule for tPA has yet been described, and the possibility
is still open that tPA is also stored in Weibel-Palade bod-
ies. The present study was therefore designed to isolate
and describe the endothelial storage particle for tPA and
to investigate whether this particle was identical to the
Weibel-Palade body, the storage granule for vWf.
 
Materials and Methods
 
Materials
 
Nycodenz was obtained from Nycomed AS (Oslo, Norway); sucrose for
density gradients from BDH (Poole, UK). Human 
 
a
 
-thrombin, BSA, cy-
cloheximide, 
 
N
 
-[3-(2-furyl)acryloyl]-
 
l
 
-phenylalanylglycylglycine and kits
for the determination of lactate dehydrogenase (LDH: No. LD-L 10) and
5
 
9
 
-nucleotidase (No. 253-3) were purchased from Sigma Chemical Co. (St.
Louis, MO). Recombinant human tPA (Activase) was from Genentech
(So. San Francisco, CA), 4-chloro-1-naphtol from Merck (Darmstadt,
Germany), and sodiumpentobarbital (Nembutal) from Sanofi (Paris, France).
Murine monoclonal antibodies against human tPA (clones ESP-4, ESP-5,
ESP-6, PAM-3) and rabbit polyclonal anti-recombinant human tPA IgG
(ADI385R) were purchased from American Diagnostica (Greenwich,
CT). The murine monoclonal anti-tPA antibodies 8C11 and 2B5 were
from Celsus Laboratories (Cincinnati, OH). Rabbit polyclonal anti–
mouse tPA was a gift from Dr P. Carmeliet (Leuven, Belgium). Rabbit
anti-vWf, murine monoclonal anti-vWf IgG, peroxidase-conjugated swine
anti–rabbit Ig, and antibody diluent were from DAKO (Glostrup, Den-
mark); rabbit anti-caveolin was from Transduction Laboratories (Mam-
head Castle, UK). Rabbit anti–human P-selectin (Coughlan et al., 1994)
was kindly donated by Dr M.C. Berndt (Prahran, Australia); rabbit anti–
human TFPI was a gift from Dr C. Lupu (Thrombosis Research Institute,
London, UK); and rabbit anti–human endothelin-1 was a gift from Dr J.
Morton (Royal Postgraduate Medical School, London, UK). Texas red-
and FITC-conjugated secondary antibodies, as well as Vectashield fluo-
rescence mounting medium were from Vector Laboratories (Peterbor-
ough, UK). Goat anti–mouse and goat anti–rabbit IgG labeled with 5- or
10-nm colloidal gold particles were purchased from Nanoprobes, Inc.
(Stony Brook, NY). Lowicryl K4M embedding medium was from Poly-
sciences (Eppelheim, Germany). All other materials used were of analyti-
cal grade.
 
Cells and Tissues
 
Human umbilical vein endothelial cells (HUVEC) were isolated by colla-
genase digestion (Jaffe et al., 1973) and cultured in Medium 199 supple-
mented with 10% (vol/vol) heat-inactivated newborn calf serum, 10%
(vol/vol) pooled human serum, 100 
 
m
 
g/ml endothelial cell growth factor,
2.5 U/ml heparin, 100 IU/ml penicillin, 100 
 
m
 
g/ml streptomycin and 2 mM
 
l
 
-glutamine, as described (van Hinsbergh et al., 1985). Confluent first pas-
sage cells were used throughout. Regulated secretion (acute release) of
tPA and vWf from HUVEC was induced in cells that had been preincu-
bated for 30 min in M199 containing 0.3 mg/ml human serum albumin,
 
l
 
-glutamine, and antibiotics, but no serum. To induce regulated secretion,
15 
 
m
 
l human 
 
a
 
-thrombin (final concentration 1 NIH U/ml) was added,
and the medium was collected after 3 min, as described (van den Eijnden-
Schrauwen et al., 1995).
The rat endothelial cell line RHE, kindly provided by Dr C.A. Diglio
(Wayne State University School of Medicine, Detroit, MI; Diglio et al.,
1988) was cultured in DME containing 10% (vol/vol) fetal calf serum, 100
IU/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 2 mM 
 
l
 
-glutamine. For ex-
periments, cells were cultured in 6-well plates and were given fresh me-
dium 24 h before an experiment.
Rat lung, mouse lung, and mouse diaphragm were obtained from Nem-
butal-anaesthetized (60 mg/kg i.p.) animals. Human lung was obtained as
anonymous and nontraceable material from lung cancer surgery. Lung
specimens for fractionation were washed free of blood and stored in cold
saline.
 
Cell and Tissue Homogenization
 
Lung tissue was finely divided by a McIlwain tissue chopper and sus-
pended in homogenization buffer (5 mM Tris-HCl, 220 mM sucrose, pH,
7.4; 10 ml buffer/gram of tissue). Confluent HUVEC (60 cm
 
2
 
, 
 
z
 
6 
 
3
 
 10
 
6
 
cells) were washed once and scraped into 2 ml homogenization buffer. For
HUVEC homogenates, which contain only low amounts of protein, this
buffer also contained 0.001% Tween-80 to improve tPA recovery (at this
concentration, Tween-80 did not lyse organelles). For the experiments on
thrombin-induced secretion, 300 cm
 
2
 
 HUVEC cultures were used and
scraped into 5 ml buffer. Cells or tissue were homogenized with ten
strokes (1500 rpm) in a glass-teflon Potter-Elvehjem tissue homogenizer,
and the homogenates were then centrifuged at 800 
 
g
 
 for 5 min at 4
 
8
 
C. An
aliquot of the supernatant (“total homogenate”) was retained to calculate
recoveries, and the remainder was fractionated.
 
Nycodenz Density Gradient Centrifugation
 
A Nycodenz solution containing 35% (wt/vol) of Nycodenz was prepared
in 5 mM Tris-HCl buffer (pH 7.4). A Nycodenz stock solution of 30% (wt/
vol) was prepared in homogenization buffer. From this stock solution, so-
lutions of Nycodenz of 27.5 to 5% (in increments of 2.5%) were prepared
in homogenization buffer. A density gradient was made in 14 ml ultracen-
trifuge tubes, starting with one ml of 35% Nycodenz, and then in eleven
steps of one ml from 30% to 5% Nycodenz, and left to equilibrate over-
night at 4
 
8
 
C. Two ml of cell or tissue homogenate was layered on top of
the gradient, and the gradient was centrifuged for 150 min at 40,000 rpm
(202,000 g
 
av
 
) in a Beckman L7-55 ultracentrifuge equipped with a SW-40
rotor, at 4
 
8
 
C. Subsequently, one ml fractions were collected, starting at the
bottom, and stored frozen. The density of the fractions was determined in
a Mettler/Paar DMA 602M density measuring cell, and ranged from 1.03-1.17
g/ml (see Results section). For additional protocol see Wanders et al. (1987).
 
Sucrose Density Gradient Centrifugation
 
A 46% (wt/vol) stock solution of sucrose (1.375 M) in 5 mM Tris-HCl, pH
7.4, was prepared (for HUVEC, 0.001% Tween 80 was added). From this
stock, sucrose solutions of 43 to 10% (in increments of 3%) were prepared
in buffer. A sucrose density gradient (46–10% sucrose; 12 steps of 1 ml)
was made in 14-ml tubes and left to equilibrate overnight at 4
 
8
 
C. 2 ml of
cell or tissue homogenate was layered on top of the gradient, and the gra-
dient was centrifuged exactly as described above for the Nycodenz gradi-
ent. 1-ml fractions were collected, and their densities were measured, as
described above. The density of the sucrose gradient fractions ranged
from 1.03 to 1.16 g/ml.
 
Assay of Fractions
 
In the fractions the following parameters were determined, using minia-
turized assays in microtiter plates. Where necessary, data were corrected
for interference by the Nycodenz or sucrose content of the fractions. Pro-
tein concentration was measured spectrophotometrically by the BCA pro-
tein assay procedure as prescribed by the manufacturer (Pierce, Rockford,
IL). tPA activity (Verheijen et al., 1982) and plasminogen activators in-
hibitor type-1 (PAI-1) activity (Verheijen et al., 1984) were determined by
spectrophotometric assay. Human tPA antigen (Schrauwen et al., 1994),
rat tPA antigen (Emeis et al., 1995), PAI-1 antigen (Nieuwenhuizen et al.,
1995), vWf antigen (Tranquille and Emeis, 1990), and cellular fibronectin
antigen (Friedman et al., 1995) were measured by ELISA.
Acid phosphatase (substrate: 
 
p
 
-nitrophenylphosphate at pH 5.0), alka-
line phosphatase (substrate: 
 
p
 
-nitrophenylphosphate at pH 10.5), neutral
esterase (substrate: 
 
p
 
-nitrophenylacetate at pH 6.6), 5
 
9
 
-nucleotidase (kit
265-3; Sigma Chemical Co.), glutamate dehydrogenase (using 
 
a
 
-ketoglu-
taric acid and NADH at pH 8.0), LDH (kit LD-L 10; Sigma Chemical
Co.), and angiotensin-converting enzyme (ACE; substrate 
 
N
 
-[3-(2-furyl)
acryloyl]-
 
l
 
-phenylalanylglycylglycine by the method of Buttery and Stuart
[1993]) were determined spectrophotometrically, using miniaturized proce-
dures adapted to a microtiterplate reader (Titertek Multiscan MCC/360; Flow
Laboratories, Irvine, Scotland). 
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Western Blotting of P-Selectin
 
The presence of P-selectin in Nycodenz fractions of HUVEC was deter-
mined semi-quantitatively by slot blotting, using a polyclonal rabbit anti–
human P-selectin (Coughlan et al., 1994). After blotting 25 
 
m
 
l of the frac-
tions on nitrocellulose paper, the paper was blocked with 10 mM Tris-HCl,
pH 7.4, containing 150 mM NaCl, 0.05% Tween 80, and 3% BSA. Subse-
quently, the paper was incubated with polyclonal rabbit anti–P-selectin
(2.3 
 
m
 
g/ml), followed by incubation with peroxidase-conjugated swine
anti–rabbit Ig, washing, and staining with 2.8 mM 4-chloro-1-naphtol plus
0.01% H
 
2
 
O
 
2
 
 in 20% methanol/80% 200 mM NaCl plus 50 mM Tris-HCl,
pH 7.4. Blots were densitometrically scanned, and the background sub-
tracted. Results will be given as relative OD units per fraction.
 
Immunocytochemistry
 
First passage HUVEC were cultured to confluency as described above on
glass coverslips coated with glutaraldehyde-crosslinked gelatin. Once con-
fluent, cells were fixed with 2% freshly depolymerized 
 
p
 
-formaldehyde in
PBS containing 5% sucrose (PBS/sucrose) for 1 h at 20
 
8
 
C. Cells were then
washed extensively in PBS/sucrose and briefly permeabilized by treat-
ment with a solution of 0.02% saponin in PBS for 10 min at 18
 
8
 
C. Cells
were then washed in PBS, quenched with 100 mM glycine in PBS, blocked
by treatment with DAKO antibody diluent supplemented with 1% (vol/
vol) normal goat or horse serum for 30 min, and incubated for 1 h at 18
 
8
 
C
with primary antibody diluted in the same blocking solution. As primary
antibodies were used, either a cocktail of monoclonal anti-tPA antibodies
(IgG 10 
 
m
 
g/ml) for single labeling or the mixture of these anti-tPA mono-
clonals with polyclonal rabbit anti-vWf IgG (diluted 1:200) for the double
immunostaining approach. To confirm the labeling pattern, in double la-
beling experiments a rabbit polyclonal anti-tPA IgG in combination with
monoclonal anti-vWf antibody was used. All specimens were extensively
washed with PBS and incubated for 1 h at 18
 
8
 
C with the secondary anti-
bodies. For single staining we used horse anti–mouse IgG-FITC (diluted
1:100 in PBS) and for double staining a mixture of horse anti–mouse IgG-
Texas red and goat anti–rabbit IgG-FITC (both diluted 1:100 in PBS).
Cells were again extensively washed in PBS, briefly rinsed in distilled wa-
ter, and mounted in Vectashield. The fluorescent specimens were exam-
ined with a confocal laser scanning unit (MRC600; Bio Rad, Hemel
Hampstead, UK) attached to a Nikon Diaphot inverted microscope. The
light source was a krypton/argon laser with main lines at 488, 568, and 674
nm. For the visualization of FITC and Texas red staining, K1 and K2 filter
blocks were used. The recorded images were merged to study colocaliza-
tion. Some samples were analyzed by serial optical sectioning in the Z-axis
of the cells, followed by computer-assisted reconstruction of the images.
Controls to ascertain for the specificity of the binding comprised either
replacement of the first antibodies with normal IgG from the same species or
incubation of the cells with the conjugates only. Staining for double labeling
of tPA and TFPI, endothelin-1, or caveolin, respectively, was performed iden-
tically as described for tPA/vWf double labeling, using as antibodies rabbit
anti-TFPI, rabbit anti-endothelin-1, and rabbit anti-caveolin, respectively.
 
Immunogold Electron Microscopy
 
For immunogold labeling, HUVEC were grown on Thermanox coverslips,
washed with serum-free medium, and fixed with 3% (wt/vol) 
 
p
 
-formalde-
hyde (freshly prepared) in PBS for 90 min at room temperature. Mouse
lung and diaphragm were fixed by perfusion with 3% 
 
p
 
-formaldehyde in
PBS for 10 min, followed by immersion fixation at room temperature for a
further 2 h. Both the cell monolayers and the mouse tissues were dehy-
drated in an ascending series of ethanol while the temperature is progres-
sively lowered, following the progressive lowering of temperature proto-
col (for details see Roth, 1989). Finally, the samples were embedded
overnight in 100% Lowicryl K4M at 
 
2
 
35
 
8
 
C. Polymerization was carried
out by irradiating tissue in gelatin capsules with UV light in a low temper-
ature embedding workstation (MS 5000; Microfield Scientific Ltd., King-
ston Bagpuize, UK) for 24 h at 
 
2
 
35
 
8
 
C, followed by hardening under UV
light at room temperature for 1 to 2 d. This sectioning was carried out on a
microtome (Ultracut; Reichert-Jung Optische Werke, Wien, Austria), and
thin sections were placed on Formvar-coated 200 mesh nickel grids. For
immunogold labeling we used the postembedding staining protocol previ-
ously described (Lupu et al., 1993). In brief, grids were floated on droplets
of PBS containing 20 mM glycine for 5 min to neutralize any free aldehyde
groups, transferred to PBS containing 1% (wt/vol) gelatine for 10 min to
neutralize “sticky” sites, and washed for 30 min in PBS containing 5%
(vol/vol) nonimmune goat serum (PBS-NGS) to quench nonspecific bind-
ing. Subsequently, the sections were incubated for 1 h at room tempera-
ture with primary antibodies. For HUVEC, we used a cocktail of murine
anti–human tPA monoclonals or a polyclonal rabbit anti–human recombi-
nant tPA IgG, both diluted 1:50 in PBS-NGS, and monoclonal mouse
anti–human vWf IgG (1:100). For the mouse tissues we have used a poly-
clonal rabbit anti–mouse tPA diluted 1:50 in PBS containing 1% NGS. Af-
ter incubation the grids were washed three times in PBS containing 1%
BSA and then incubated for 1 h at room temperature in the same dilution
buffer containing the appropriate gold-labeled secondary antibody.
Thereafter, grids were washed with PBS and distilled water, stained with
uranyl actate and lead citrate, and observed in a transmission electron mi-
croscope (EM201; Philips, Eindhoven, The Netherlands).
 
Results
 
Density Gradient Centrifugation of Rat Lung on a 
Nycodenz Gradient
 
Rat lung was chosen for the first experiments, since it is, of
all rat tissues, richest in tPA (Padró et al., 1990). In pilot
experiments, using a Nydodenz gradient with density
range 1.05–1.27 g/ml, all tPA and vWf was recovered at
densities 
 
,
 
1.18 g/ml. In subsequent experiments, there-
fore, a more shallow gradient (density range 1.03 to 1.17 g/
ml) was employed. In such a gradient (Fig. 1, 
 
a–d
 
), tPA
was found as a single symmetrical peak, with a maximum
at density 1.11–1.12 g/ml. Both tPA activity and tPA anti-
gen were found at the same position in the gradient (Fig. 1
 
a
 
). The correlation between tPA antigen and activity in
the 14 fractions was in all four experiments 
 
.
 
0.97. In those
two fractions that contained maximal amounts of tPA,
 
z
 
50% of tPA (Fig. 1 
 
a
 
) and 6–7% of protein (Fig. 1, 
 
c
 
 and
 
d
 
) was recovered. vWf antigen also peaked at density
1.11–1.12 g/ml, but in addition showed a second, smaller
peak at density 1.06–1.07 g/ml (Fig. 1 
 
b
 
). Tissue protein,
and most of the marker enzymes measured, showed peak
values in the fractions with densities of 1.03 to 1.08 g/ml
(Fig. 1, 
 
c
 
 and 
 
d
 
). Typically, 
 
.
 
70% of the protein was re-
covered in the these fractions. Maximal alkaline phos-
phatase and ACE activity (used as plasma membrane
marker enzymes) were found around 
 
d
 
 
 
5
 
 1.05–1.08 g/ml;
acid phosphatase (a marker for lysosomes), neutral es-
terase, and 5
 
9
 
-nucleotidase (markers for microsomes)
around 
 
d
 
 
 
5
 
 1.05–1.07 g/ml, and LDH (a marker for the cy-
tosol) 
 
z
 
d
 
 
 
5
 
 1.03 g/ml. Only glutamate dehydrogenase ac-
tivity, a marker enzyme for mitochondria, was recovered
at 
 
d
 
 
 
5
 
 1.11–1.12 g/ml, the density of maximal tPA and vWf
concentrations. Cellular fibronectin, a marker of connec-
tive tissue contamination, was found at density 1.06 g/ml.
Recentrifugation of the two-peak fractions (
 
d
 
 
 
5
 
 1.11–
1.12 g/ml, diluted 1:1 with homogenization buffer to re-
duce density) on an identical Nycodenz gradient resulted
in recovery of tPA and vWf at the density of the original
fractions (Fig. 2 
 
a
 
). To decide whether the distribution of
tPA in the gradient might have been due to binding of par-
ticle-free tPA to a particle of 
 
d
 
 
 
5
 
 1.11–1.12 g/ml, recombi-
nant human tPA (Activase; final concentration 50 ng/ml)
was added to a rat lung homogenate before gradient cen-
trifugation. Subsequently, we separately measured the ex-
ogenously added human tPA antigen and the endogenous
rat tPA antigen by species-specific tPA ELISA assays. Rat
tPA was recovered as a single peak at its normal density,
while the human tPA was found distributed diffusely 
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through the gradient (Fig. 2 
 
b
 
). Upon ultracentrifugation
of a lung homogenate in homogenization buffer without
Nycodenz (
 
d
 
 
 
5
 
 1.03 g/ml), 
 
.
 
90% of tPA and vWf was re-
covered at the bottom of the tube. After ultracentrifuga-
tion in homogenization buffer without Nycodenz but now
containing 1% Triton X-100 to lyse organelles, tPA and
vWf were diffusely distributed through the gradient (not
shown). From these data it was concluded that almost all
tPA was present in rat lung homogenates in sedimentable
particles of 
 
d
 
 
 
5
 
 1.11–1.12 g/ml.
To see whether any of the tPA or vWf could be ascribed
to tPA or vWf in a pathway of ongoing protein synthesis,
rats were pretreated with cycloheximide (2 mg/kg in vivo)
at 3 h before being killed. This procedure inhibits rat pro-
tein synthesis fully but does not significantly influence the
size of the storage pool in rat lung (Tranquille and Emeis,
1989). Cycloheximide treatment did not significantly influ-
Figure 1. Gradient centrifu-
gation of rat lung homoge-
nate on a Nycodenz density
gradient. In this and in all
subsequent figures, percent-
ages refer to percentage per
fraction of total activity (or
antigen) recovered in the 14
fractions of a gradient. The
numbers 1–14 of the frac-
tions are displayed on the X
axis. (a) The percentage per
fraction of tPA antigen (d)
and the percentage per frac-
tion of tPA activity (m) are
shown as mean 6 SD (n 5
4). The mean density of the
fractions is also indicated
(r). (b) The percentage per
fraction of vWf antigen (j)
is shown as mean 6 SD (n 5
4). The mean density of the
fractions is given as (r). (c)
The mean (n 5 4) percentage
per fraction of cell protein
(d;  dashed line), alkaline
phosphatase (s), angioten-
sin-converting enzyme (h), 59-nucleotidase (,), and cellular fibronectin (j). (d) The mean (n 5 4) percentage per fraction of cell pro-
tein (d; dashed line), LDH (.), acid phosphatase (n), neutral esterase (h), and glutamate dehydrogenase (j; dashed line).
Figure 2. (a) A rat lung ho-
mogenate was centrifuged on
a Nycodenz density gradient,
and fractions 6 and 7, con-
taining the highest concen-
trations of tPA and vWf,
were recentrifuged after dilu-
tion on an identical Nyco-
denz gradient. Shown are the
percentage per fraction of
tPA antigen (j) and vWf an-
tigen (h) in the second den-
sity gradient. The fraction
numbers 1–14 are shown on the X axis. The position of the original fractions 6 and 7 of the first gradient is indicated by the line. (b) Hu-
man recombinant tPA was added to a rat lung homogenate to a final concentration of 50 ng/ml, followed by centrifugation on a Nyco-
denz density gradient. Shown on the Y axis are the percentage per fraction of endogenous rat tPA antigen (d) and of exogenously
added human tPA antigen (.). The fraction numbers 1–14 are given on the X axis. Rat and human tPA antigen concentrations were de-
termined by species-specific ELISA assays.
ence the distribution of tPA or vWf from rat lung homoge-
nate. Also, the amount of vWf present around d 5 1.06 g/ml,
which might have been located in the protein synthesis
pathway, was unchanged (data not shown). As discussed
above, no tPA peak is present at this density.
Fractionation of a cell homogenate from a rat heart en-
dothelial cell line (Diglio et al., 1988) on a Nycodenz gra-
dient showed that the bulk of tPA (antigen and activity)
was found distributed similarly as in rat lung, though at a
slightly lower density of 1.09–1.10 g/ml (not shown). This
cell line does not synthetize vWf.
Density Gradient Centrifugation of Rat Lung on a 
Sucrose Gradient
Using a sucrose gradient of d 5 1.03–1.16 g/ml, tPA (both
antigen and activity) was found at the same density (1.11–Emeis et al. Endothelial tPA Storage Granule 249
1.12 g/ml) as in Nycodenz gradients (Fig. 3). vWf, how-
ever, showed a different distribution than in Nycodenz
gradients, as no vWf peak was present in fractions 6 and 7
of sucrose density gradients. This resulted (Fig. 3) in a
clear separation of tPA (peak in fractions 6 and 7) and
vWf (peak in fractions 10 and 11). Marker enzymes for
subcellular fractions, including the mitochondrial marker
glutamate dehydrogenase, showed, in sucrose gradients, a
similar distribution as in Nycodenz gradients (not shown).
Density Gradient Centrifugation of Human Lung
Homogenates of human lung were fractionated on a Nyco-
denz density gradient and on a sucrose density gradient.
The distribution of tPA (antigen and activity) and vWf
was more complex in human lung, and less tPA and vWf
was present in fractions 7 and 8 of the gradients, compared
to rat lung. In sucrose gradients, vWf had practically disap-
peared from fraction 7 and 8. Of the vWf recovered, 14% 6
3 was found in fractions 7 and 8 in Nycodenz gradients, but
only 2% 6 2 in sucrose gradients (mean 6 SD, n 5 4; P ,
0.01). No such difference between Nycodenz and sucrose
gradients was found for the tPA content of fractions 7 and
8 (19% 6 4 in Nycodenz gradients versus 16% 6 4 in su-
crose gradients, n 5 4, P 5 0.33).
Density Gradient Centrifugation of HUVEC
First passage HUVEC (60 cm2/experiment) were fraction-
ated on Nycodenz gradients. In Fig. 4, the averaged distri-
bution of tPA antigen and of vWf is shown for five such
fractionations. Slight differences in density distribution,
especially for tPA, were found between cultures, but the
overall distribution pattern (Fig. 4) resembled that found
in rat lung. For tPA, the major peak was found at d 5
1.105 g/ml (fraction 6), with a (variably pronounced)
shoulder at d 5 1.13 g/ml (fraction 4). A second, smaller
peak was seen at d 5 1.06 g/ml (fraction 10). vWf had a
single major peak (d 5 1.105–1.115; fractions 5 and 6),
and, in three out of five cultures, a small shoulder at d 5
1.06 g/ml (fraction 11). No sucrose density gradient cen-
trifugation was performed on HUVEC.
Thrombin Stimulation of tPA Secretion
For experiments involving thrombin stimulation of regu-
lated secretion (acute release) of tPA, 300-cm2 HUVEC
cultures were used that had been preincubated for 24 h
with 1 mM sodiumbutyrate to increase tPA synthesis and
storage (Kooistra et al., 1987). HUVEC were stimulated
with 1 NIH U/ml of human a-thrombin for 3 min (van den
Eijnden-Schrauwen et al., 1995), scraped into cold buffer,
and homogenized. Control cultures, not treated with
thrombin, were run in parallel. After thrombin, a loss of
tPA antigen from the high density range of the gradient
(fractions 5–8) was observed, compared to the parallel
control cultures. Two typical cultures (out of five) are
shown in Fig. 5, a and b. In the experiment shown in Fig. 5
a, tPA disappeared mainly from density range 1.11–1.12 g/ml
(fractions 6–8), while in the experiment shown in Fig. 5 b,
tPA was reduced in fractions 4–6 (density 1.14 g/ml). The
differences between cultures possibly reflect greater ex-
perimental variation in cultured HUVEC than in experi-
ments involving rat lungs (note the small SDs in Fig. 1, a
and b).
Although the differences in tPA concentration in the
fractions induced by thrombin were relatively small, im-
munocytochemistry of tPA antigen in these cells showed
that, after 3 min of thrombin stimulation, the granular tPA
staining had disappeared from most cells (Fig. 6), while in
other cells a weak granular staining persisted. This loss of
staining is in agreement with biochemical data, which
showed that, after 1 NIH U/ml thrombin stimulation, no
further acute release of tPA could be obtained by ionomy-
cin (van den Eijnden-Schrauwen et al., 1995). By Western
blotting, P-selectin was detected (using the 300-cm2 HU-
VEC cultures) in the density range 1.10–1.15. After throm-
Figure 3. A rat lung homogenate was centrifuged on a sucrose
density gradient. On the Y axis, the percentage per fraction of
tPA antigen (d) and of vWf antigen (j) are shown. Note that the
distribution of tPA antigen is practically identical to the distribu-
tion on a Nycodenz density gradient (Figs. 1 a and 2). The distri-
bution of vWf on the sucrose gradient is, however, very different,
due to an extensive loss of vWf from the density range 1.10–1.12
g/ml (compare Figs. 1 b and 2). The density of the fractions from
the sucrose gradient is indicated as well (r) and is very similar to
the density profile of Nycodenz gradients.
Figure 4. Percentage per fraction of tPA antigen (d) and of vWf
(j) in Nycodenz gradients after centrifugation of homogenate
prepared from 60 cm2 HUVEC cells. Shown are mean 6 SD of
five homogenates from separate cell cultures.The Journal of Cell Biology, Volume 139, 1997 250
bin stimulation, the distribution of P-selectin shifted (one
to two fractions) to higher densities (Fig. 7) and became
more intense.
Immunohistochemical Localization of tPA and vWf
in HUVEC
The cellular localization of tPA in HUVEC was visualized
by indirect immunofluorescence labeling and confocal mi-
croscopy, as well as at the ultrastructural level by postem-
bedding immunogold labeling and electron microscopy. In
formaldehyde-fixed, saponin-permeabilized HUVEC, tPA
showed, by immunofluorescence, well defined granular
staining in the cytoplasm of the cells (Fig. 8 f; compare
with Fig. 6). To enable precise localization of the fluores-
cence, some specimens were analyzed by serial optical sec-
tioning followed by computer-assisted reconstruction of
the image. Serial optical sectioning along the Z-axis re-
vealed that granular tPA staining was localized in the peri-
nuclear, organelle-rich area as well as in the attenuated ar-
eas at the cell edges (Fig. 9).
The granular localization of tPA was confirmed by
postembedding immunogold labeling of ultrathin sections
of HUVEC (Fig. 8, a and b) and of vascular endothelial
cells in mouse lung and diaphragm capillaries (Fig. 8, d
and e). The gold particles delineating tPA were present
throughout the cells, often in clusters over small, fairly
electron-dense vesicles, which in favorable sections could
be seen to be surrounded by a membrane (Fig. 8, b, d, and
e). The location of the gold particles suggested that they
were superimposed on the small vesicles that are abun-
dantly present in endothelial cells after routine fixation
and embedding and that are much smaller than Weibel-
Palade bodies. The gold particles delineating vWf were de-
tected on much larger, elongated particles, which con-
tained densely packed fibrillar material and had the mor-
phological characteristics compatible with Weibel-Palade
bodies (Fig. 8 c, W-Pb).
No Colocalization of tPA with vWf in HUVEC
To further differentiate between tPA- and vWf-containing
granules in HUVEC, we performed double immunolabel-
ing for tPA and vWf with Texas red- and FITC-labeled
secondary antibodies and simultaneous visualization of
the two proteins by confocal microscopy. To detect
whether the two proteins were colocalized, the two images
were merged; any superimposed green and red areas
Figure 5. Distribution of tPA
antigen (pg/ml) from a con-
trol HUVEC culture (d) and
from a culture treated with 1
NIH U/ml of human a-throm-
bin for 3 min (s). Data from
two separate experiments are
shown (a and b). HUVEC
homogenate was prepared for
each condition from a 300-cm2
HUVEC culture (first pas-
sage), pretreated for 24 h
with 1 mM sodiumbutyrate
(see Materials and Methods). Both control and thrombin-treated cells had been obtained from the same primary HUVEC culture. On
the X axis the fraction numbers are indicated. The difference in density between corresponding fractions from the thrombin-treated and
control Nycodenz gradient fractionations was always ,0.004 g/ml. Note that in Fig. 6 a, tPA is lost mainly from fractions 6–10, while in Fig.
6 b, tPA is lost from fractions 4–8. See text for details.
Figure 6. Immunocytochem-
ical staining for tPA in first
passage control HUVEC
(left) and in HUVEC after
induction of regulated secre-
tion by 1 NIH U/ml of hu-
man a-thrombin for 3 min
(right). Cells were fixed and
stained as described in Mate-
rials and Methods. The fig-
ures show a semiquantitative
measurement of fluorescence
intensity, using pseudocolor
banding. Note that after
thrombin treatment, some
cells have lost all granular
tPA staining, while the other
cells show a reduced staining
intensity. Bar, 25 mm.Emeis et al. Endothelial tPA Storage Granule 251
would then appear in yellow. As illustrated by Fig. 8, f–h
(f, tPA; panel g, vWf), no colocalization of the two anti-
gens was observed (h, in which e and f are superimposed,
so that colocalization of tPA and vWf would show as yel-
low). Control experiments gave no labeling in all condi-
tions tested (not shown).
No Colocalization of tPA with endothelin-1, caveolin, 
or TFPI in HUVEC
Using identical techniques of indirect immunofluores-
cence and confocal microscopy as described above for
vWf, we looked for colocalization of tPA with three other
endothelial proteins: endothelin-1 and tissue factor path-
way inhibitor, which are both secreted by HUVEC, and
caveolin, a component of caveolae (Lisanti et al., 1994).
As shown in Fig. 10, no evidence for colocalization of
these proteins with tPA in HUVEC was obtained. We
show elsewhere (Lupu et al., 1997) that caveolin and TFPI,
but not tPA, colocalize in HUVEC in caveolae.
Discussion
Remarkably, the first studies on the subcellular fraction-
ation of plasminogen activators (at that time called “fi-
brinolysokinase activators,” now known to be tPA) from
tissue date 1950 (Tagnon and Palade, 1950; Lewis and Fer-
guson, 1950) and describe that the enzyme activity resides
in the “large granule and microsome” fractions of tissue
homogenates (Lewis and Ferguson, 1950). Apart from a
few similar studies in the mid-sixties (Lack and Ali, 1964;
Ali and Lack, 1965; Sugiyama, 1965; Beard et al., 1968),
which located tissue PA activity to lysosomes, no major
advances in the localization of tPA in tissues were made.
Recently, it was shown that, in cells transfected with tPA,
tPA is sorted to a granular compartment in the regulated
pathway (Harrison et al., 1996).
Meanwhile, the Weibel-Palade body has been firmly es-
tablished to be the storage particle for vWf. This particle,
first described as an endothelial organelle characterized by
specific morphological features (Weibel and Palade, 1964),
was subsequently shown to be the storage organelle for
vWf in endothelial cells (for review see Reinders et al.,
1988; Wagner 1990, 1993; Mayadas and Wagner, 1991;
Hop and Pannekoek, 1996).
In clinical and in experimental (in vivo and in vitro)
studies, the regulated secretion (acute release) of tPA and
vWf generally occurs simultaneously (Tranquille and
Emeis, 1989, Emeis, 1995, van den Eijnden-Schrauwen et
al., 1995). This might be due to the fact that the cellular
mechanisms involved in tPA and vWf release from endo-
thelial cells are very similar but also due to colocalization
of the proteins in a single particle. The question whether
tPA and vWf are colocalized is of practical importance,
because colocalization would make it impossible to induce
selectively the release of either the procoagulant protein
vWf or the anticoagulant protein tPA.
Our data show that tPA and vWf are not located in a
single storage granule but in granules that can be sepa-
rated by sucrose density gradient centrifugation and that
can be visualized as separate by light- and electron-micro-
scopical immunocytochemistry. Ultracentrifugation of rat
lung homogenate in buffer showed that tPA (and vWf)
were present in a sedimentable particle, from which the
proteins could be released by Triton treatment. By density
gradient ultracentrifugation on a Nycodenz gradient, the
density of the particle was determined to be 1.11–1.12 g/ml.
The distribution of tPA in the Nycodenz gradient was not
due to nonspecific binding of soluble tPA (Fig. 2 b), while
the particle was stable upon recentrifugation (Fig. 2 a). In
previous experiments, we have shown that tissue stores of
tPA, including tPA stores in rat lung, are metabolically
highly stable, hardly showing any decrease 3 h after pro-
tein synthesis has been inhibited by cycloheximide (Tran-
quille and Emeis, 1989). Cycloheximide treatment did not
cause any change in the density distribution of tPA and
vWf either. The large peak of tPA (activity and antigen)
found after density gradient fractionation of lung must
thus be either active tPA stored in a storage pool, or tPA
present in a metabolically inert pool, e.g., extracellular
tPA bound to connective tissue. A contribution from ex-
tracellular tPA is, however, most unlikely, because con-
nective tissue components (e.g., cellular fibronectin, see
Fig. 1 d) equilibrate at a much lower density. The tPA
present at d 5 1.11–1.12 was, moreover, enzymatically
fully active, while extracellular tPA would have been
present largely as an inactive complex with its inhibitor
PAI-1 (Kooistra et al., 1986; Fearns et al., 1996).
In Nycodenz gradients, the distribution of vWf and tPA
was nearly identical, suggesting that the two proteins could
be present in a single storage granule (Figs. 1, a and b, and
2 a). The equilibrium density of this putative storage gran-
ule was, moreover, similar to the equilibrium density of
Weibel-Palade bodies in other types of density gradient,
e.g., Percoll gradients (Reinders et al., 1984; Ewenstein et
al., 1987).
In sucrose gradients, however, the distribution of vWf
differed from that of tPA. tPA showed essentially the
same density distribution as in Nycodenz gradients, but
vWf had disappeared from the d 5 1.11–1.12 g/ml frac-
tions (compare Fig. 3 with Figs. 1, a and b, and 2 a). This
observation showed that the two proteins were not stored
Figure 7. Distribution of P-selectin–reactive material, as deter-
mined by Western blotting and densitometric scanning, in Nyco-
denz gradient centrifugation fractions of homogenates from con-
trol (s) and thrombin-treated (d) HUVEC cultures. Cell culture
and preparatory conditions were as in Fig. 5. Note the increase in
P-selectin immunoreactive material in fractions 2–8 after throm-
bin treatment.The Journal of Cell Biology, Volume 139, 1997 252
in the same granule in rat lung. An explanation for the
density shift of vWf might be destabilization of the Wei-
bel-Palade body by sucrose, leading to collapse, or dehy-
dration by the hypertonic sucrose solutions, leading to a
change in density. The tPA storage particle would then be
immune to these forces. Similar to rat lung, sucrose den-
sity centrifugation resulted in human lung in a significant
loss of vWf antigen from the d 5 1.11–1.12 g/ml fractions
(from 14% in Nycodenz to 2% in sucrose), without caus-
ing a loss of tPA from these fractions (from 19 to 16%).
The distribution of tPA from rat heart endothelial cells
was very similar to that from rat lung. In human lung and
HUVEC (Figs. 4 and 5) the distribution pattern of tPA
and vWf was more complex, although peaks of tPA and
vWf could still clearly be identified at d 5 1.11–1.12 g/ml.
Presumably, the presence of other cells (including blood
platelets), more connective tissue in the lung, and more
subendothelial matrix in HUVEC contributed to the more
complex patterns observed in homogenates from human
lung and from HUVEC.
Figure 8. Localization of
tPA and vWf in endothelial
cells: immunogold labeling in
HUVEC of tPA (a and b)
and of vWf (c), and immu-
nogold labeling of tPA in
murine capillary endothelial
cells in lung (d) and dia-
phragm (e). HUVEC were
fixed in 3% p-formaldehyde
in PBS, and mouse endothe-
lial cells were perfusion
fixed with the same fixative.
The samples were dehy-
drated at progressively
lower temperature, embed-
ded in Lowicryl K4M resin at
2358C, and immunolabeled
on grid with 10-nm colloidal
gold, as described in Materi-
als and Methods. tPA is
found, both in situ and in
vitro, in vesicular structures
with an electron-dense con-
tent (a, b, d, and e, arrows).
For comparison, a coated
vesicle is indicated on the
surface of a HUVEC (cv).
vWf was detected in struc-
tures with the typical charac-
teristics of Weibel-Palade
bodies (c, W-Pb): elongated
structures containing densely
packed fibrilar material. f–h
show double immunofluores-
cent labeling of HUVEC with
antibodies specific for tPA (f)
and vWf (g). The images col-
lected from both fluores-
cence channels were superim-
posed in h. Note that the red
and green granules are clearly
different, and that in the su-
perimposed figure of h almost
no yellow (red over green)
grains are observed. Bars:
(a–e) 0.2 mm; (f–h) 25 mm.Emeis et al. Endothelial tPA Storage Granule 253
Two other small particles have been isolated from en-
dothelial cells. Caveolae (Lisanti et al., 1994; Schnitzer et
al., 1995) are plasmalemmal vesicles characterized by the
presence of, among others, GPI-anchored proteins and ca-
veolin. Recently, a storage particle for endothelin-1 has
been isolated from bovine aortic endothelial cells (Harri-
son et al., 1995). It is not likely that tPA storage granules
are identical to caveolae, since the former are much denser
than caveolae and do not contain plasma membrane mark-
ers such as alkaline phosphatase (Fig. 1 c), as do caveolae
(Lisanti et al., 1994). In addition, by double immunofluo-
rescent staining, tPA- and caveolin-containing structures
were different (Fig. 10). Tissue factor pathay inhibitor
(TFPI) has, in HUVEC, also been localized (Lupu et al.,
1995a) by immunocytochemistry in a particle, which con-
tains, in addition, caveolin but not tPA (Lupu et al., 1997),
in agreement with Fig. 10. Together, these data suggest
that the tPA-containing particle does not contain caveolin,
ET-1, and TFPI. We also found no evidence for a colocal-
ization of tPA with ET-1 (Fig. 10 i). The data thus suggest,
though they certainly do not prove, that of the proteins
mentioned above, those four that are secreted from HU-
VEC (vWf, tPA, ET-1, and TFPI) may be located in dif-
ferent structures, which opens the possibility that endothe-
lial secretory proteins are packaged in separate secretory
pathways.
Stimulation, by thrombin, of acute secretion of tPA and
vWf from HUVEC (van den Eijnden-Schrauwen et al.,
1995, 1997) resulted in a loss of tPA from the higher-den-
sity fractions (d 5 1.10–1.14). This loss coincided with the
appearance of tPA (and vWf) in the culture medium and
thus likely reflects the secretion of tPA (vWf) from its
storage pool. The loss was accompanied by a slight shift
to higher densities. Stimulation with 1 NIH U of human
a-thrombin for 3 min induces maximal release of tPA
from HUVEC, since neither an increase in thrombin con-
centration above 1 U/ml nor subsequent stimulation with
the calcium ionophore ionomycin induced any additional
tPA secretion (van den Eijnden-Schrauwen et al., 1995).
Stimulation with 1 U/ml of thrombin was also accompa-
nied by a complete loss of granular tPA staining in some
cells and a severe reduction in tPA staining in the others
(Fig. 6). The quantatively, only moderate disappearance of
tPA from homogenates of thrombin-stimulated cells was
therefore surprising and may reflect the presence, in en-
dothelial cell cultures, of relatively large amounts of tPA
outside the secretory pathway.
Thrombin-induced release of tPA was accompanied
(Fig. 7) by a shift to slightly higher densities and an in-
crease in immunoreactivity of P-selectin, a component of
Weibel-Palade bodies (Wagner, 1993). Whether the tPA
storage granule also contained P-selectin could not be de-
cided from the data and is still under investigation. The
cell biological substrate of this density shift of P-selectin
remains unexplained. It could reflect the fusion of multiple
particles, as described by Richardson et al. (1994) in rat
endothelial cells after thrombin stimulation in vivo. The
remarkable increase in P-selectin immunoreactivity after
thrombin (Fig. 8) is also not explained but might be due to
an increased accessibility of P-selectin to antibody after
thrombin treatment.
The morphological observations on HUVEC, obtained
using immunocytochemical labeling procedures with con-
focal microscopy and immunoelectronmicroscopy on thin
sections, showed that tPA was localized throughout the cy-
toplasm of HUVEC in small vesicular structures, which
differed from Weibel-Palade bodies in size and morphol-
ogy. Particles staining for vWf were larger and contained a
more electron-dense and fibrillar core. No significant colo-
calization of tPA- and vWf-containing particles was ob-
served in double immunocytochemical labeling experi-
ments. In summary, the morphological data support and
extend the biochemical data that tPA-containing vesicles
and vWf-containing Weibel-Palade bodies are distinct en-
tities.
Recent observations (van den Eijnden-Schrauwen, 1996;
van den Eijnden-Schrauwen et al., 1997) on regulated se-
cretion of tPA and vWf from HUVEC have shown that
several mechanisms are involved in (thrombin-induced)
Figure 9. Sequential display of 10 optical sections in the Z-axis
through HUVEC. The cells were double stained for tPA and
vWf, and the two proteins were simultaneously visualized in se-
rial optical sections from the apical (section 1) to the basal (sec-
tion 10) side of the cells. tPA is detected throughout the cell,
while vWf is distributed mainly in the perinuclear area. Bar, 25 mm.The Journal of Cell Biology, Volume 139, 1997 254
Figure 10. Double staining of first passage HUVEC for tPA (left column, a, d, and g) and either TFPI (b), caveolin (e), or endothelin-1
(h). The panels in the right column represent the superposition of staining for tPA (green) with staining (red) for either TFPI (c), caveo-
lin (f), or endothelin-1 (i). In case of colocalization of two proteins, the resultant superimposed image in the right hand column is yellow.
Note that only in the case of tPA and endothelin-1 (i) in some cells is superimposition observed. For technical details, see Materials and
Methods. Bar, 25 mm.Emeis et al. Endothelial tPA Storage Granule 255
regulated secretion of tPA and vWf. Regulated secretion
of vWf is mainly dependent upon an increase in intracellu-
lar calcium and calcium influx, while regulated secretion of
tPA requires, in addition, the activation of one or more G
proteins (van den Eijnden-Schrauwen et al., 1997). The
two secretory pathways also show different sensitivities to
actin depolymerization (van den Eijnden-Schrauwen, 1996).
Such differences in secretory mechanisms presuppose the
existence of two separate storage particles. The present
data provide evidence that two such storage particles in-
deed exist: the Weibel-Palade body for vWf, and a sepa-
rate, newly described, particle for tPA.
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